Approval · Notice of Compliance 1379 · 2000
PERMAX: Notice of Compliance 1379
Issued November 1, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1379
- Date
- November 1, 2000
- Company
- Draxis Health Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: as early therapy in the treatment of parkinson's disease, without concomitant levodopa therapy
- Therapeutic class
- Dopamine agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PERMAX | Not yet assigned | — |
Medicinal ingredients
- PERGOLIDE MESYLATE 0.05 MG per TAB
- PERGOLIDE MESYLATE 0.25 MG per TAB
- PERGOLIDE MESYLATE 1 MG per TAB